VOLITIONRX LTD
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
VNRX$0.20+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| $ | $ | |
| ASSETS | ||
| Current Assets | ||
| Cash and cash equivalents | 1,117,028 | 3,264,429 |
| Accounts receivable, net | 317,808 | 110,574 |
| Prepaid expenses | 433,680 | 338,660 |
| Other current assets | 192,409 | 343,145 |
| Total Current Assets | 2,060,925 | 4,056,808 |
| Property and equipment, net | 4,027,849 | 4,429,152 |
| Operating lease right-of-use assets | 495,749 | 599,816 |
| Intangible assets, net | 316,704 | 313,747 |
| Total Assets | 6,901,227 | 9,399,523 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current Liabilities | ||
| Accounts payable | 2,918,768 | 2,766,178 |
| Accrued liabilities | 4,211,828 | 3,476,903 |
| Deferred revenue | 353,846 | 230,000 |
| Management and directors’ fees payable | 80,939 | 30,086 |
| Current portion of long-term debt | 890,571 | 860,223 |
| Current portion of financing lease liabilities | 54,377 | 46,737 |
| Current portion of operating lease liabilities | 250,336 | 221,755 |
| Current portion of grants repayable | 117,093 | 60,979 |
| Warrant liability | 20,978 | 97,886 |
| Derivative liability | 913,742 | - |
| Current portion of convertible note payable, net | 2,418,275 | - |
| Total Current Liabilities | 12,230,753 | 7,790,747 |
| Long-term debt, net of current portion | 5,818,354 | 3,952,846 |
| Deferred revenue, net of current portion | 21,938,462 | 22,663,400 |
| Finance lease liabilities, net of current portion | 317,859 | 328,338 |
| Operating lease liabilities, net of current portion | 276,558 | 410,686 |
| Grants repayable, net of current portion | 473,652 | 361,242 |
| Convertible note payable, net of current portion | 1,438,400 | - |
| Total Liabilities | 42,494,038 | 35,507,259 |
| Stockholders’ Deficit | ||
| Common stock | ||
| Authorized: 325,000,000 shares of common stock, at $0.001 par value | ||
| Issued and outstanding: 125,779,769 shares and 96,097,485 shares, respectively | 125,780 | 96,098 |
| Additional paid-in capital | 218,824,268 | 204,154,994 |
| Accumulated other comprehensive income | (295,071) | 385,631 |
| Accumulated deficit | (252,901,370) | (229,544,343) |
| Total VolitionRx Limited Stockholders’ Deficit | (34,246,393) | (24,907,620) |
| Non-controlling interest | (1,346,418) | (1,200,116) |
| Total Stockholders’ Deficit | (35,592,811) | (26,107,736) |
| Total Liabilities and Stockholders’ Deficit | 6,901,227 | 9,399,523 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.